Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01260168 · ClinicalTrials.gov registry record
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
A clinical trial, sponsored by Exact Sciences Corporation.
- Completed
- Registry status
- 435
- Enrollment target
NCT01260168: Completed study, sponsored by Exact Sciences Corporation.
NCT01260168 is a clinical trial that has completed, run by Exact Sciences Corporation. The registered enrollment target is 435 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01260168 has completed, sponsored by Exact Sciences Corporation.
- COMPLETED
- Registry status
- 435 participants
- Enrollment target
Study Summary
The objective of this study is to confirm the sensitivity of a stool DNA test for detection of colorectal cancer and pre-cancer. Another objective is to provide anonymous, clinically characterized specimens for a bio-repository for future colorectal cancer-related test development.
Primary Outcome
The diagnostic test under development is a multi-marker stool test for detecting CRC and pre-cancer in a general screening application. The primary objective of this study is to confirm the sensitivity of the optimal DNA marker panel.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 435 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-11 |
What the finished NCT01260168 record still lists
NCT01260168 is an observational study that tracks outcomes without assigning an intervention. The registered 435 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01260168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01260168 about?
NCT01260168 is a clinical study titled "Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies". The objective of this study is to confirm the sensitivity of a stool DNA test for detection of colorectal cancer and pre-cancer. Another objective is to provide anonymous, clinically characterized specimens for a bio-repository for future colorectal cancer-related test development.
What is the current status of trial NCT01260168?
This trial is currently completed. The enrollment target is 435 participants. The study started on 2010-10. Estimated completion is 2013-11.
Who is sponsoring clinical trial NCT01260168?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- NCT07088926 · 435 participants · Phase 2
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia